What we have learned from RegistHER?
(HER2+ mBC n=1023)
•
Use of surgery and trastuzumab following CNS metastasis were each associated with
longer survival
(Brufsky et al. Clinical Cancer Res 2011)
•
Elderly patients had higher rates of cardiovascular disease and less first-line
trastuzumab. Use of trastuzumab associated to longer PFS and a non-significant
improvement in OS in this population
(Kauffman, BCRT 2012)
•
Dual targeting of HRs and HER2 is associated with prolonged PFS and OS; adjusted HR
0.50 in patients that had first line CT-trastuzumab-HT vs without HT
(Tripathy et al. The
Oncologist 2013)
•
De novo
MBC had better outcome than recurrent disease, which may be related to
prior drug exposure (may have implicactions for clinical trial design and interpretation)
(Yardley et al. BCRT 2014)
